Navigation Links
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Date:8/19/2007

SEATTLE, Aug. 17 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced publication of results from a Phase 1 study of NEUVENGE, an investigational active cellular immunotherapy, in the August 20 issue of the Journal of Clinical Oncology. The article highlights the safety profile, immune response and clinical activity of NEUVENGE in women with HER2/neu-positive breast cancer who have failed standard therapy.

"In addition to demonstrating that NEUVENGE was safe and well tolerated, the T-cell responses seen in these patients and the prolonged disease stabilization in the absence of other anti-cancer therapies in many patients is promising," said John W. Park, M.D., associate clinical professor of medicine and neurosurgery at the University of California, San Francisco and lead author of the publication. "These observations are encouraging and are suggestive of the clinical benefit of NEUVENGE, particularly in light of the aggressive cancer seen in these patients who had progressed while on standard therapy. The findings warrant additional studies of NEUVENGE for the many women with advanced breast cancer who have exhausted many of their treatment options."

Study Design

The Phase 1 study (D2000-2) was conducted to evaluate the safety and immunologic activity of NEUVENGE in patients with HER2-overexpressing metastatic breast cancer who had failed standard therapy, including prior treatment with chemotherapy and trastuzumab. All patients had experienced disease progression while on standard therapy. There were 19 patients enrolled in the study with 18 patients receiving treatment with NEUVENGE. Patients underwent three infusions of NEUVENGE at Weeks 0, 2, and 4 following randomizati
'/>"/>

SOURCE Dendreon Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... October 02, 2014 Freeslate, ... research solutions for biopharmaceutical development, today announced highlights ... 24, 2014 at GlaxoSmithKline (GSK) in Ware, UK. ... of best practices in high throughput research and ... leaders gathered together to discuss the challenges and ...
(Date:10/2/2014)... The National Institutes of Health ... grant today to develop an electrode array system ... the brain works through unprecedented resolution and scale. ... efforts to support President Obama's BRAIN (Brain Research ... effort to revolutionize our understanding of the human ...
(Date:10/2/2014)... , Oct. 2, 2014  NKT Therapeutics ... Administration has granted Fast Track designation to NKTT120, ... treatment of sickle cell disease.  NKTT120 is a ... a regulatory T cell that has been demonstrated ... in preclinical models of sickle cell disease.  Fast ...
(Date:10/1/2014)... 01, 2014 METTLER TOLEDO’s newly improved ... precision balances as well as a dual range ... performance, the new SmartPan™ weighing pan delivers results up ... On all balances, ergonomic design details mean users no ... working for long periods in front of the balance. ...
Breaking Biology Technology:Freeslate European Summit Highlights Best Practices in High Throughput Research and Data Management 2NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 2NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 3NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 4FDA Grants Fast Track Designation to NKT Therapeutics' NKTT120 for the Treatment of Sickle Cell Disease 2METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 2METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 3
... Reportlinker.com announces that a new market research ... Orthopedic Biomaterials, The World Market ... products, which can be organic or synthetic in ... fracture to facilitate healing or to compensate for ...
... 3, 2011 EntreMed, Inc. (Nasdaq: ENMD ... treatment of cancer today announced the presentation of clinical ... platinum-resistant ovarian cancer patients.   The data were presented ... A. Matulonis, medical director of gynecologic oncology at Dana-Farber ...
... 3, 2011 Asmacure Ltee, a clinical-stage ... agonists for the treatment of asthma and other inflammatory ... as chief executive officer.  With a solid foundation established ... it progresses its lead compound, a potential new treatment ...
Cached Biology Technology:Reportlinker Adds Orthopedic Biomaterials, The World Market 2Reportlinker Adds Orthopedic Biomaterials, The World Market 3Reportlinker Adds Orthopedic Biomaterials, The World Market 4EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 2EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 3EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 4Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 2Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 3
(Date:9/30/2014)... on Earth, but when the climate changes and temperatures ... The amount of time needed to adjust to new ... in the future, reveals a new study from researchers ... journal Proceedings of the Royal Society B . ... of greenhouse gases in the atmosphere. The greenhouse effect ...
(Date:9/30/2014)... in Munich report that a new class of ... chemotherapeutic drugs. They have also pinpointed the relevant ... anti-tumor agents. , Researchers led by LMU,s ... the Technische Universitt Mnchen have identified a class ... in the fight against malignant tumors. The compound ...
(Date:9/30/2014)... Sept. 30, 2014  Spectra Automation, a ... the biotech and power generation industries, announced ... Bioprocess Manager, an easy-to-use and cost-effective data ... bioprocess development laboratories. Most ... and analyzer systems. Accessing and consolidating data ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... criminals, requires evidence and witnesses; but on the scale ... easier said than done. A team of ... Arizona State University may soon change that. Under a ... a new way to close the gaps in the ...
... Sarasota FL., December 17, 2007 Researchers at ... of the EASE (Exhale Airway Stents for Emphysema) Trial, ... treatment that may offer a significant new, minimally-invasive option ... focuses on a procedure called airway bypass that involves ...
... latest American Chemical Society (ACS) News Service Weekly PressPac with ... News.,Please credit the individual journal or the American Chemical Society ... FOR IMMEDIATE USE EXCEPT ARTICLE #5, which is embargoed for ... ARTICLE #1 FOR IMMEDIATE RELEASE A faster, ...
Cached Biology News:ASU researchers use NASA satellites to improve pollution modeling 2Researchers at Sarasota Memorial Health Care System to study airway bypass treatment for emphysema 2American Chemical Society's Weekly PressPac -- Dec. 12, 2007 2American Chemical Society's Weekly PressPac -- Dec. 12, 2007 3American Chemical Society's Weekly PressPac -- Dec. 12, 2007 4American Chemical Society's Weekly PressPac -- Dec. 12, 2007 5American Chemical Society's Weekly PressPac -- Dec. 12, 2007 6American Chemical Society's Weekly PressPac -- Dec. 12, 2007 7American Chemical Society's Weekly PressPac -- Dec. 12, 2007 8American Chemical Society's Weekly PressPac -- Dec. 12, 2007 9American Chemical Society's Weekly PressPac -- Dec. 12, 2007 10
For demonstration of Helicobacter pylori...
... efficient interfacing with mass spectrometry. Improved ... demands for benefits like these have ... routine applications. Standard HPLC systems, however, ... to operate with smaller bore columns ...
... is used in conjunction with your existing apoptosis ... apoptosis according to your existing procedure (also reserve ... control). Once you have induced apoptosis in your ... population and incubate the cells for an additional ...
Kit Components: Anti-Acetylated Histone H3 Salmon Sperm DNA/Protein A Agarose All necessary buffers. ...
Biology Products: